These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 17977968)

  • 1. Effects of partial deletions within the human immunodeficiency virus type 1 V3 loop on coreceptor tropism and sensitivity to entry inhibitors.
    Nolan KM; Jordan AP; Hoxie JA
    J Virol; 2008 Jan; 82(2):664-73. PubMed ID: 17977968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a human immunodeficiency virus type 1 V3 deletion mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-bound receptor.
    Nolan KM; Del Prete GQ; Jordan AP; Haggarty B; Romano J; Leslie GJ; Hoxie JA
    J Virol; 2009 Apr; 83(8):3798-809. PubMed ID: 19193800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct molecular pathways to X4 tropism for a V3-truncated human immunodeficiency virus type 1 lead to differential coreceptor interactions and sensitivity to a CXCR4 antagonist.
    Del Prete GQ; Leslie GJ; Haggarty B; Jordan AP; Romano J; Hoxie JA
    J Virol; 2010 Sep; 84(17):8777-89. PubMed ID: 20573813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein.
    Huang W; Toma J; Fransen S; Stawiski E; Reeves JD; Whitcomb JM; Parkin N; Petropoulos CJ
    J Virol; 2008 Jun; 82(11):5584-93. PubMed ID: 18353956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Replication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists.
    Lin G; Bertolotti-Ciarlet A; Haggarty B; Romano J; Nolan KM; Leslie GJ; Jordan AP; Huang CC; Kwong PD; Doms RW; Hoxie JA
    J Virol; 2007 Sep; 81(18):9956-66. PubMed ID: 17609282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.
    Laakso MM; Lee FH; Haggarty B; Agrawal C; Nolan KM; Biscone M; Romano J; Jordan AP; Leslie GJ; Meissner EG; Su L; Hoxie JA; Doms RW
    PLoS Pathog; 2007 Aug; 3(8):e117. PubMed ID: 17722977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a dual-tropic human immunodeficiency virus (HIV-1) strain derived from the prototypical X4 isolate HXBc2.
    Xiang SH; Pacheco B; Bowder D; Yuan W; Sodroski J
    Virology; 2013 Mar; 438(1):5-13. PubMed ID: 23369572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
    Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
    Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain.
    Gray L; Roche M; Churchill MJ; Sterjovski J; Ellett A; Poumbourios P; Sherieff S; Wang B; Saksena N; Purcell DF; Wesselingh S; Cunningham AL; Brew BJ; Gabuzda D; Gorry PR
    J Virol; 2009 Jun; 83(11):5430-41. PubMed ID: 19321618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations.
    Huang W; Eshleman SH; Toma J; Fransen S; Stawiski E; Paxinos EE; Whitcomb JM; Young AM; Donnell D; Mmiro F; Musoke P; Guay LA; Jackson JB; Parkin NT; Petropoulos CJ
    J Virol; 2007 Aug; 81(15):7885-93. PubMed ID: 17507467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.
    Jiang X; Feyertag F; Meehan CJ; McCormack GP; Travers SA; Craig C; Westby M; Lewis M; Robertson DL
    J Virol; 2015 Nov; 89(22):11457-72. PubMed ID: 26339063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of naturally occurring basic amino acid substitutions in the human immunodeficiency virus type 1 subtype E envelope V3 loop on viral coreceptor usage and cell tropism.
    Kato K; Sato H; Takebe Y
    J Virol; 1999 Jul; 73(7):5520-6. PubMed ID: 10364300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hybrid approach for predicting coreceptor used by HIV-1 from its V3 loop amino acid sequence.
    Kumar R; Raghava GP
    PLoS One; 2013; 8(4):e61437. PubMed ID: 23596523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.
    Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural basis for coreceptor selectivity by the HIV type 1 V3 loop.
    Cardozo T; Kimura T; Philpott S; Weiser B; Burger H; Zolla-Pazner S
    AIDS Res Hum Retroviruses; 2007 Mar; 23(3):415-26. PubMed ID: 17411375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional impact of HIV coreceptor-binding site mutations.
    Biscone MJ; Miamidian JL; Muchiri JM; Baik SS; Lee FH; Doms RW; Reeves JD
    Virology; 2006 Jul; 351(1):226-36. PubMed ID: 16631222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutagenesis of CXCR4 identifies important domains for human immunodeficiency virus type 1 X4 isolate envelope-mediated membrane fusion and virus entry and reveals cryptic coreceptor activity for R5 isolates.
    Chabot DJ; Zhang PF; Quinnan GV; Broder CC
    J Virol; 1999 Aug; 73(8):6598-609. PubMed ID: 10400757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage.
    Svicher V; Alteri C; Artese A; Zhang JM; Costa G; Mercurio F; D'Arrigo R; Alcaro S; Palù G; Clementi M; Zazzi M; Andreoni M; Antinori A; Lazzarin A; Ceccherini-Silberstein F; Perno CF;
    Antivir Ther; 2011; 16(7):1035-45. PubMed ID: 22024519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage.
    Verrier F; Borman AM; Brand D; Girard M
    AIDS Res Hum Retroviruses; 1999 May; 15(8):731-43. PubMed ID: 10357469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substitution of gp120 C4 region compensates for V3 loss-of-fitness mutations in HIV-1 CRF01_AE co-receptor switching.
    Yu Y; Feng Y; Zhou Z; Li K; Hu X; Liao L; Xing H; Shao Y
    Emerg Microbes Infect; 2023 Dec; 12(1):e2169196. PubMed ID: 36647730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.